Cutler Group LP Allakos Inc. Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$5.66 - $8.42 $3,962 - $5,894	-700 Reduced 28.0%	1,800 $15,000
Q3 2022 Oct 25, 2022	SELL	$3.02 - $6.12 $172 - $348	-57 Reduced 2.23%	2,500 $15,000
Q2 2022 Aug 04, 2022	SELL	$2.6 - $6.14 $11,811 - $27,894	-4,543 Reduced 63.99%	2,557 $8,000
Q1 2022 Apr 14, 2022	SELL	$5.08 - $9.81 $73,903 - $142,715	-14,548 Reduced 67.2%	7,100 $40,000
Q4 2021 Jan 18, 2022	BUY	$8.55 - $111.89 $165,006 - $2.16 Million	19,299 Added 821.58%	21,648 $211,000
Q3 2021 Oct 26, 2021	BUY	$76.53 - $110.43 $164,462 - $237,314	2,149 Added 1074.5%	2,349 $248,000
Q2 2021 Jul 19, 2021	SELL	$85.37 - $114.1 $95,870 - $128,134	-1,123 Reduced 84.88%	200 $17,000
Q1 2021 Apr 26, 2021	BUY	$109.73 - $153.66 $67,593 - $94,654	616 Added 87.13%	1,323 $151,000
Q3 2020 Oct 27, 2020	SELL	$66.43 - $90.99 $116,252 - $159,232	-1,750 Reduced 71.23%	707 $57,000
Q2 2020 Jul 22, 2020	BUY	$44.04 - $80.69 $8,323 - $15,250	189 Added 8.33%	2,457 $176,000
Q1 2020 May 07, 2020	BUY	$44.49 - $93.39 $29,719 - $62,384	668 Added 41.75%	2,268 $100,000
Q4 2019 Feb 06, 2020	BUY	$66.49 - $137.73 $106,383 - $220,367	1,600 New	1,600 $152,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $82.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.